Below is an article about how the strong start of Novo’s Wegovy tablet has reportedly revolutionized the weight-loss drug market, while challenging Lilly’s previous dominance in this field. Oral GLP-1 drugs are expanding the market significantly by attracting new user groups with their affordability and ease of use compared to traditional injections.
According to the article, this development is “forcing” investors to re-evaluate the market situation; even though Lilly brought its own Foundayo pill to the market, Novo’s head start and aggressive marketing have surprised analysts.
And while the pills are important to both Novo and Lilly, analysts say they won’t define either company.
“Yes it’s shaking things up, but I still think Lilly has enough components to excel,” BMO’s Seigerman said. “And while Novo may win with this, they need more than one win to be the champion.”
https://www.cnbc.com/2026/05/04/novo-nordisk-wegovy-pill-beating-eli-lilly-foundayo-early.html